By WHAV Staff |
Eddie S. Glaude Jr. (Courtesy photograph.)
“The Ethics of Anti-Racism” is the subject of a Northern Essex Community College White Fund Lecture in early May.
Eddie S. Glaude Jr., chair of the African American Studies Department at Princeton University, discusses the topic during the free online talk Wednesday, May 5, at 6:30 p.m. The college says “his presentation will deconstruct the idea of whiteness and the way in which it determines the distribution of advantage and disadvantage in this country.”
An author, political commentator, public intellectual and passionate educator, Glaude calls on his audiences to engage in an ongoing critique of racism’s manifestations, challenging people to think more carefully and systematically about racial issues.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
The Closing Bell Featuring Sigyn Therapeutics
Sigyn Therapeutics, Inc.April 21, 2021 GMT
The Interactive Videoconference Occurs Today at 4pm Eastern / 1pm Pacific Time
SAN DIEGO, April 21, 2021 (GLOBE NEWSWIRE) via NewMediaWire Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome, announces that its Chairman and CEO, Jim Joyce, will be featured on the Closing Bell videoconference hosted by Force Family Offices at 4pm Eastern today. This interactive event provides investors with an opportunity to talk directly with Mr. Joyce regarding the advancement of Sigyn Therapy™, a novel blood purification technology designed to treat sepsis and other life-threatening conditions that are induced by cytokine storm syndrome. Also participating in the event will
Endo Tools Therapeutics Secures €8 Million ($9.5M) in Series D Funding Led by White Fund
Developing innovative, minimally invasive medical devices for gastroenterologists, company plans to seek regulatory clearance in the US and reimbursement in European countries
Endo Tools Therapeutics (ETT), developers of advanced endoscopic medical devices for use by gastroenterologists, today announces the closing of a Series D funding round of €8 million ($9.5M), led by White Fund. The transaction is supported by new private investors and the existing investors (FPIM-SFPI, Epimède, Chagral Invest and private investors).
ETT will use the Series D funding to submit a regulatory marketing submission for its medical devices to the Food and Drug Administration (FDA) in the US for soft tissue approximation. ETT also intends to seek further reimbursement within the EU. Lastly, the funding will help to continue R&D efforts into new products and indications, collate evidence on device capabilit